Researchers at the University of Kansas Medical Center, Dartmouth’s and Dartmouth-Hitchcock’s Norris Cotton Cancer Center, Brown University School of Public Health, and the University of California San Francisco have introduced a novel immune-profiling method capable of reporting specific immune cell types using only DNA from blood, rather than from fresh cell samples.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.
